Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma

Inclusion Criteria: * General * Able and willing to provide written informed consent. * Able and willing to comply with the study protocol. * Males and females ≥ 18 years of age. * Asthma-related * Asthma diagnosed by a respiratory physician ≥12 months prior to study enrolment based on the Global Initiative for Asthma (GINA) 2021 guidelines. * ACQ ≥1.5 at screening. * Methacholine PC20 ≤ 4 mg/mL OR ≥15% decrease in FEV1 during saline inhalation for sputum induction OR ≥15% improvement in FEV1 after bronchodilator during the screening period. * Criteria met for moderate or severe asthma defined by GINA 2021 guidelines, i.e. treatment with low, medium or high dose ICS (\<250 mcg, 251 - 500 mcg, \>500 mcg of fluticasone equivalent/day respectively) plus another controller. Patients on prednisone would not be excluded, as long as they meet the rest of the inclusion criteria. * FeNO \>25 ppb OR ≥3% sputum eosinophils (preferred) OR blood eos ≥300/µL during the screening period. * History of ≥1 exacerbation in the previous year. Exclusion Criteria: * General \-- Participation in any clinical trial of an investigational agent or procedure within six months prior to screening or during the study. * Medical conditions and treatment history * History of anaphylaxis to any previous biologic therapy received. * Receipt of live attenuated vaccine within 30 days, receipt of COVID vaccine within 28 days, known or suspected COVID infection at the time of enroll…